Gain Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Gain Therapeutics Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Bethesda
Headquarters state / province: Maryland
Headquarters country: United States
Fiscal year end: December
Ticker symbol: GANX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001819411
EIN: 85-1726310

Board of directors

Follow this board

Claude Nicaise · Director
Since 2023
Dov A. Goldstein M.D. · Director
Since 2023
Eric I. Richman · Director
Since 2023
Gene Mack · Director · CEO, President
Since 2025
Gwen A. Melincoff · Director
Since 2023
Hans Peter Hasler · Director
Since 2023
Jeffrey Scott Riley · Director
Since 2023
Khalid Islam · Director · Executive Chairman
Since 2023
Matthias Alder · Director · Chief Executive Officer
Since 2023

Chief executives

Matthias Alder · Chief Executive Officer

Dates unknown

Gene Mack · CEO, President

Dates unknown

Director election results

Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

5 of this board's directors also sit on 8 other boards. 8 are in the same sector.

Shared director Other board Same sector

Chemomab Therapeutics Ltd. American Depositary Share Same sector
via Claude Nicaise and Gwen A. Melincoff
Collegium Pharmaceutical Inc. Same sector
via Gwen A. Melincoff
Coya Therapeutics Inc. Same sector
via Dov A. Goldstein M.D.
Fennec Pharmaceuticals Inc. Same sector
via Khalid Islam
Filana Therapeutics Inc. Same sector
via Claude Nicaise
Minerva Neurosciences Inc Same sector
via Hans Peter Hasler
Protalix BioTherapeutics Inc. (DE) Same sector
via Gwen A. Melincoff
Sarepta Therapeutics Inc. Same sector
via Claude Nicaise

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Aug 9, 2024	Khalid Islam Director, Officer (Executive Chairman)	Open-market purchase	+50,000	$1.00	$50,000
Aug 9, 2024	Mack Gene Officer (CFO and Interim CEO)	Open-market purchase	+14,400	$1.01	$14,544
Jul 1, 2024	Eric I. Richman Director	Open-market purchase	+5,000	$1.23	$6,150
Jul 1, 2024	Eric I. Richman Director	Open-market purchase	+12,000	$1.21	$14,520
Mar 28, 2024	Jeffrey Scott Riley Director	Open-market purchase	+30,000	$3.86	$115,800
Mar 26, 2024	Matthias Alder Director, Officer (Chief Executive Officer)	Option exercise	+18,750	—	—
Mar 26, 2024	Matthias Alder Director, Officer (Chief Executive Officer)	Option exercise	+825	—	—
Mar 26, 2024	Matthias Alder Director, Officer (Chief Executive Officer)	Option exercise	+637	—	—
Mar 26, 2024	Matthias Alder Director, Officer (Chief Executive Officer)	Shares withheld for tax	−6,085	$4.06	$24,705
Dec 21, 2023	Matthias Alder Director, Officer (Chief Executive Officer)	Open-market sale	−206	$2.46	$507
Dec 20, 2023	Matthias Alder Director, Officer (Chief Executive Officer)	Option exercise	+637	—	—
Dec 7, 2023	Matthias Alder Director, Officer (Chief Executive Officer)	Open-market sale	−1,820	$2.50	$4,550
Oct 1, 2023	Matthias Alder Director, Officer (Chief Executive Officer)	Option exercise	+825	—	—
Sep 20, 2023	Eric I. Richman Director	Option exercise	+54,900	—	—
Sep 20, 2023	Matthias Alder Director, Officer (Chief Executive Officer)	Option exercise	+2,550	—	—

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Gain Therapeutics Inc.

Who is the CEO of Gain Therapeutics Inc.?

Matthias Alder is Gain Therapeutics Inc.'s Chief Executive Officer.

How many directors are on Gain Therapeutics Inc.'s board?

Gain Therapeutics Inc.'s board has 9 directors: Claude Nicaise, Dov A. Goldstein M.D., Eric I. Richman, Gene Mack, Gwen A. Melincoff, Hans Peter Hasler, Jeffrey Scott Riley, Khalid Islam and Matthias Alder.

How is Gain Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="gain-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.